ORPHA:1147
Sheldon-Hall syndrome
Also known as: DA2B · Distal arthrogryposis multiplex congenita type 2B · Distal arthrogryposis type 2B · Freeman-Sheldon syndrome variant · SSH
Publications
134
61.2th percentile
Trials
0
Interventional, condition-specific
Researchers
983
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A form of distal arthrogryposis characterized by multiple non- contractures of the distal joints of the limbs, in the absence of a primary neurological and/or muscle disease, and distinctive facial features, such as a triangular face shape, downslanting palpebral fissures, small mouth and high arched palate.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011128
- UMLS:C1834523
Additional Mondo synonyms (2)
arthrogryposis, distal, type 2B · distal arthrogryposis type 2B
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
134 matched papers (74 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
134
134 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
134 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
74 in the last 10 years · medium confidence · 61.2th percentile (publications denominator)
Phrase hits: 134 · MeSH hits: 0
Who's working on it?
983
Distinct author names in 134 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bamshad MJ9 papers · 2023
Department of Pediatrics, Department of Genome Sciences, Seattle Children's Hospital, Seattle, WA 98105, USA.
Papers in Europe PMC - 02Li J9 papers · 2022
Key Laboratory of Reproductive Health of Liaoning Province, Shenyang, China.
Papers in Europe PMC - 03Carey JC7 papers · 2015
Department of Pediatrics, University of Utah, Salt Lake City, UT 84108, USA.
Papers in Europe PMC - 04Dobbs MB7 papers · 2022
Paley Orthopaedic and Spine Institute, West Palm Beach, FL 33407, USA.
Papers in Europe PMC - 05Gurnett CA7 papers · 2022
Department of Neurology, Washington University in St Louis, St Louis, MO 63130, USA.
Papers in Europe PMC - 06Li X7 papers · 2022
Key Laboratory of Reproductive Health of Liaoning Province, Shenyang, China.
Papers in Europe PMC - 07Poling MI7 papers · 2024
Department of Applied Physiology, FSRG deGruyter-McKusick Institute of Health Sciences, Buckhannon, West Virginia, USA.
Papers in Europe PMC - 08Bamshad M6 papers · 2024
Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City 84132-1001.
Papers in Europe PMC - 09Chamberlain RL6 papers · 2020
Department of Applied Physiology, FSRG deGruyter-McKusick Institute of Health Sciences, Buckhannon, West Virginia, USA.
Papers in Europe PMC - 10Han W6 papers · 2015
Key Laboratory of Reproductive Health of Liaoning Province, Shenyang, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 2 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Sheldon-Hall syndrome" OR "Distal arthrogryposis multiplex congenita type 2B" OR "Distal arthrogryposis type 2B" OR "Freeman-Sheldon syndrome variant" OR "arthrogryposis, distal, type 2B"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Sheldon-Hall syndrome" OR "Distal arthrogryposis multiplex congenita type 2B" OR "Distal arthrogryposis type 2B" OR "Freeman-Sheldon syndrome variant" OR "arthrogryposis, distal, type 2B"
Study-type breakdown: 0 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: DA2B; SSH
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T16:31:15.835Z